Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

PURPOSE: CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses follo...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Sharma, Padmanee, Siefker-Radtke, Arlene, de Braud, Filippo, Basso, Umberto, Calvo, Emiliano, Bono, Petri, Morse, Michael A., Ascierto, Paolo A., Lopez-Martin, Jose, Brossart, Peter, Rohrberg, Kristoffer, Mellado, Begoña, Fischer, Bruce S., Meadows-Shropshire, Stephanie, Abdel Saci, Callahan, Margaret K., Rosenberg, Jonathan
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2019
主題:
RAPID COMMUNICATION
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879315/
https://ncbi.nlm.nih.gov/pubmed/31100038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00538
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料